Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 67-kDa laminin receptor (67LR) is a non-integrin cell surface receptor that plays a dual role as a structural component of the 40S ribosome (as its 37-kDa precursor, RPSA) and a high-affinity receptor for laminin (UniProt P08865). In the context of gene therapy, 67LR serves as a critical co-receptor for the adeno-associated virus serotype 9 (AAV9), facilitating viral attachment and internalization into target cells, particularly in the central nervous system and muscle tissues (Akache et al., 2006). AAV9 transduction also depends on other co-receptors, including terminal galactose residues for initial attachment and the adeno-associated virus receptor (AAVR/KIAA0319L) for endosomal escape and trafficking (Pillay et al., 2016). Beyond its role in viral entry, 67LR is frequently overexpressed in various cancers, where it correlates with increased metastatic potential and poor prognosis by mediating tumor cell adhesion to the basement membrane (Montuori et al., 2012). It also serves as a receptor for other pathogens, including the Dengue virus and prions, and is the primary target for the green tea polyphenol epigallocatechin gallate (EGCG), which induces cancer-specific apoptosis through 67LR-mediated signaling (Tachibana et al., 2004). Therapeutic strategies involving 67LR include its utilization for targeted AAV-mediated gene delivery and the development of antibodies or small molecules to inhibit its role in cancer progression.
67LR facilitates AAV9 attachment and internalization into host cells. In cancer, it promotes metastasis by mediating cell adhesion to laminin-1 in the basement membrane. It also acts as a receptor for EGCG, triggering a cGMP-dependent apoptotic pathway.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 67-kDa laminin receptor (RPSA) (67LR).